These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27592718)

  • 21. Cholesterol treatment and changes in guidelines in an academic medical practice.
    Schoen MW; Salas J; Scherrer JF; Buckhold FR
    Am J Med; 2015 Apr; 128(4):403-9. PubMed ID: 25460526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment with statins: lowering of cholesterol or more?].
    Rutishauser J
    Praxis (Bern 1994); 2006 Jan; 95(4):107-10. PubMed ID: 16485605
    [No Abstract]   [Full Text] [Related]  

  • 23. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
    de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
    Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment for dyslipidemia--a strategy for the prevention of atherosclerosis].
    Seishima M
    Rinsho Byori; 2013 Apr; 61(4):334-41. PubMed ID: 23855190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [No documentation for overtreatment with statins].
    Jensen GB
    Ugeskr Laeger; 2011 Sep; 173(38):2363; author reply 2363. PubMed ID: 22034664
    [No Abstract]   [Full Text] [Related]  

  • 27. [Mechanisms of statin nephroprotective actions].
    Chmielewski M; Zdrojewski Z; Rutkowski B
    Przegl Lek; 2002; 59(7):519-22. PubMed ID: 12516241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.
    Stern AM; Schurdak ME; Bahar I; Berg JM; Taylor DL
    J Biomol Screen; 2016 Jul; 21(6):521-34. PubMed ID: 26962875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High HDL may not protect the heart. Concentrate on lowering LDL for now, experts advise.
    Harv Heart Lett; 2012 Sep; 23(1):6. PubMed ID: 23097807
    [No Abstract]   [Full Text] [Related]  

  • 30. [Stroke, cholesterol and statins--are there new data about stroke prevention?].
    Ferbert A
    Dtsch Med Wochenschr; 2001 Jun; 126(22):664-70. PubMed ID: 11450627
    [No Abstract]   [Full Text] [Related]  

  • 31. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.
    Coppola G; Novo S
    Arch Med Res; 2007 Jul; 38(5):479-88. PubMed ID: 17560452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins.
    Kobayashi M; Chisaki I; Narumi K; Hidaka K; Kagawa T; Itagaki S; Hirano T; Iseki K
    Life Sci; 2008 Apr; 82(17-18):969-75. PubMed ID: 18402982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts.
    Goodarzi MO; Taylor KD; Scheuner MT; Antoine HJ; Guo X; Shah PK; Rotter JI
    Pharmacogenomics J; 2007 Feb; 7(1):66-73. PubMed ID: 16755277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
    Choi SH; Chae A; Miller E; Messig M; Ntanios F; DeMaria AN; Nissen SE; Witztum JL; Tsimikas S
    J Am Coll Cardiol; 2008 Jul; 52(1):24-32. PubMed ID: 18582631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Masana L; Pedro-Botet J; Civeira F
    Atherosclerosis; 2015 May; 240(1):161-2. PubMed ID: 25795557
    [No Abstract]   [Full Text] [Related]  

  • 37. [First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
    Einecke D
    MMW Fortschr Med; 2003 Dec; 145(51-52):38. PubMed ID: 14974329
    [No Abstract]   [Full Text] [Related]  

  • 38. [When cholesterol lowering drugs should not be too expensive. Statins are especially effective in secondary prevention].
    Thomas HP; Kassner U; Steinhagen-Thiessen E
    MMW Fortschr Med; 2000 Jul; 142(30):33-4. PubMed ID: 10955017
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [An updated overview of the high intensity lipid lowering therapy in high cardiovascular risk patients].
    Pedro-Botet J; Pintó X
    Clin Investig Arterioscler; 2016; 28(1):19-30. PubMed ID: 26657098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.